Sci Rep:前列腺癌中应激诱导隧道纳米管利于治疗适应性

2019-06-04 AlexYang MedSci原创

隧道纳米管(TNTs)是基于肌动蛋白的膜结构,可以将远距离的细胞物理上联系起来,从而进行细胞间的交流。最近,有研究人员确定了前列腺癌(PCa)中,TNTs在应激诱导适应性和治疗抵抗性中的作用。雄激素受体(AR)阻断和代谢应激能够诱导TNTs,但是在正常前列腺上皮或者成骨细胞中不存在上述情况。共培养试验分析阐释了在应激和非应激条件下,PCa细胞的TNT形成的增强,从应激的PCa细胞到造骨细胞TNT形

隧道纳米管(TNTs)是基于肌动蛋白的膜结构,可以将远距离的细胞物理上联系起来,从而进行细胞间的交流。

最近,有研究人员确定了前列腺癌(PCa)中,TNTs在应激诱导适应性和治疗抵抗性中的作用。雄激素受体(AR)阻断和代谢应激能够诱导TNTs,但是在正常前列腺上皮或者成骨细胞中不存在上述情况。共培养试验分析阐释了在应激和非应激条件下,PCa细胞的TNT形成的增强,从应激的PCa细胞到造骨细胞TNT形成也增强。应激诱导的伴侣聚类蛋白和YB-1定位在TNTs中,并通过TNTs双向运输,还以PI3K/AKT和Eps8依赖的方式促进TNT的形成。AR拮抗剂诱导的AR变体能够调节对AR途径抑制的抗性,该过程也能够增强TNT的产生和恢复聚类蛋白或者YB-1抑制的TNT的形成。TNT功能丧失能够敏化PCa细胞对治疗诱导的细胞死亡。

最后,研究人员指出,他们的数据确定了一个与应激诱导的伴侣蛋白和AR变体、PI3K/AKT信号、肌动蛋白重建和TNT调节的细胞间交流有关的机制网络,并验证了应激适应细胞生存。

原始出处:

Alexander Kretschmer, Fan Zhang, Syam Prakash Somasekharan et al. Stress-induced tunneling nanotubes support treatment adaptation in prostate cancer. Sci Rep. 24 May 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1445285, encodeId=bf76144528581, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Thu Jun 06 03:49:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621025, encodeId=7c0716210252d, content=<a href='/topic/show?id=dccc94e01c9' target=_blank style='color:#2F92EE;'>#适应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94701, encryptionId=dccc94e01c9, topicName=适应性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b13a20191510, createdName=huhuaidong394, createdTime=Thu Jun 06 03:49:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023710, encodeId=c6df2023e10ea, content=<a href='/topic/show?id=24189858651' target=_blank style='color:#2F92EE;'>#隧道纳米管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98586, encryptionId=24189858651, topicName=隧道纳米管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sun Oct 27 12:49:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040470, encodeId=5f5e10404e077, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jun 04 15:49:00 CST 2019, time=2019-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367262, encodeId=347136e2620b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Jun 04 13:19:29 CST 2019, time=2019-06-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1445285, encodeId=bf76144528581, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Thu Jun 06 03:49:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621025, encodeId=7c0716210252d, content=<a href='/topic/show?id=dccc94e01c9' target=_blank style='color:#2F92EE;'>#适应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94701, encryptionId=dccc94e01c9, topicName=适应性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b13a20191510, createdName=huhuaidong394, createdTime=Thu Jun 06 03:49:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023710, encodeId=c6df2023e10ea, content=<a href='/topic/show?id=24189858651' target=_blank style='color:#2F92EE;'>#隧道纳米管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98586, encryptionId=24189858651, topicName=隧道纳米管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sun Oct 27 12:49:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040470, encodeId=5f5e10404e077, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jun 04 15:49:00 CST 2019, time=2019-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367262, encodeId=347136e2620b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Jun 04 13:19:29 CST 2019, time=2019-06-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1445285, encodeId=bf76144528581, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Thu Jun 06 03:49:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621025, encodeId=7c0716210252d, content=<a href='/topic/show?id=dccc94e01c9' target=_blank style='color:#2F92EE;'>#适应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94701, encryptionId=dccc94e01c9, topicName=适应性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b13a20191510, createdName=huhuaidong394, createdTime=Thu Jun 06 03:49:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023710, encodeId=c6df2023e10ea, content=<a href='/topic/show?id=24189858651' target=_blank style='color:#2F92EE;'>#隧道纳米管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98586, encryptionId=24189858651, topicName=隧道纳米管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sun Oct 27 12:49:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040470, encodeId=5f5e10404e077, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jun 04 15:49:00 CST 2019, time=2019-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367262, encodeId=347136e2620b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Jun 04 13:19:29 CST 2019, time=2019-06-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1445285, encodeId=bf76144528581, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Thu Jun 06 03:49:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621025, encodeId=7c0716210252d, content=<a href='/topic/show?id=dccc94e01c9' target=_blank style='color:#2F92EE;'>#适应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94701, encryptionId=dccc94e01c9, topicName=适应性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b13a20191510, createdName=huhuaidong394, createdTime=Thu Jun 06 03:49:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023710, encodeId=c6df2023e10ea, content=<a href='/topic/show?id=24189858651' target=_blank style='color:#2F92EE;'>#隧道纳米管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98586, encryptionId=24189858651, topicName=隧道纳米管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sun Oct 27 12:49:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040470, encodeId=5f5e10404e077, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jun 04 15:49:00 CST 2019, time=2019-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367262, encodeId=347136e2620b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Jun 04 13:19:29 CST 2019, time=2019-06-04, status=1, ipAttribution=)]
    2019-06-04 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1445285, encodeId=bf76144528581, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Thu Jun 06 03:49:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621025, encodeId=7c0716210252d, content=<a href='/topic/show?id=dccc94e01c9' target=_blank style='color:#2F92EE;'>#适应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94701, encryptionId=dccc94e01c9, topicName=适应性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b13a20191510, createdName=huhuaidong394, createdTime=Thu Jun 06 03:49:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023710, encodeId=c6df2023e10ea, content=<a href='/topic/show?id=24189858651' target=_blank style='color:#2F92EE;'>#隧道纳米管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98586, encryptionId=24189858651, topicName=隧道纳米管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sun Oct 27 12:49:00 CST 2019, time=2019-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040470, encodeId=5f5e10404e077, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jun 04 15:49:00 CST 2019, time=2019-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367262, encodeId=347136e2620b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Jun 04 13:19:29 CST 2019, time=2019-06-04, status=1, ipAttribution=)]
    2019-06-04 1ddf0692m34(暂无匿称)

    学习了,谢谢分享

    0

相关资讯

Brit J Cancer:基于CE-MS的尿液生物标记可以区分显著性前列腺癌和非显著性前列腺癌

低风险前列腺癌的恶化较为缓慢,但是当发展为转移性疾病时则是致死的。因此,一种能够检测显著性前列腺癌的非侵入测试方法是需要的,从而来指导患者的治疗。毛细管电影/质谱可以用来鉴定尿液中的多肽,这些多肽也许能够准确的检测显著性前列腺癌。研究人员在823名患者(PSA<15ng/ml)活检前收集了尿液样本,并在包含543名(nSig=98; nnon-Sig=445)患者的训练集和280名患者的鉴定

J Natl Cancer Inst:男默女泪!215万男性随访38年发现,输精管结扎与前列腺癌风险增加15%有关

出于各种原因,男性结扎相对来说一直是个比较禁忌的话题,大家对它的了解也并不多。每当看到有人问“结扎之后是不是就不能做爱做的事了”的时候,奇点糕就觉得莫名好笑,你们对结扎到底是有什么误解啊?

Int Urol Nephrol:MRI的指数肿瘤体积作为根治性前列腺切除术后临床和病理结果的预测因子研究

根治性前列腺癌切除术(RP)样本的指数肿瘤体积(ITV)表现出了与不良病理和肿瘤结果的相关性。最近,有研究人员评估了从前列腺多参数MRI(mpMRI)中计算获得的ITV对预测不良临床和病理结果的价值。研究人员的数据来源于一个前瞻性维护的、单中心的数据库,这些患者在RP之前经历了mpMRI(2007-2016)。研究发现,在455名患者中,前列腺外扩张(EPE)、淋巴结入侵(LNI)、精囊入侵(SV

J Cell Biochem:Notch1蛋白的抑制能够减少肿瘤生长

Notch1在许多癌症中,包括前列腺癌(PCa),起着促进癌症的作用。利用γ-分泌酶抑制剂对Notch家族成员的整体抑制能够在小鼠模型中显著的抑制PCa的生长。然而,Notch的整体抑制表现出了显著的毒性,原因是在正常的细胞生理中,许多不同的Notch家族成员均具有相关的功能。最近,有研究人员将雄激素依赖的VCaP和不依赖雄激素的DU145细胞系对小鼠进行皮下注射。这些小鼠进行对照抗体1B7.11

Iran Biomed J:新型聚腺苷二磷酸核糖聚合酶(RARP)抑制剂AZD2461能够下调VEGF表达和诱导前列腺癌细胞凋亡

前列腺癌(PCa)是一种异质性疾病,目前的治疗手段并不是基于分子层面。最近有报道表明,RARP抑制剂对具有同源重组缺陷的细胞具有明显的毒性,尤其是那些BRCA变异背景的细胞。因此,最近有研究人员评估了是否PTEN表达状态对侵入性PCa细胞对RARP抑制剂AZD2461的敏感性具有影响。研究发现,MTT结果表明了AZD2461对PC-3细胞的抑制作用要比DU145细胞显著更高(处理后48小时的IC5

Cancer Res:前列腺癌风险新的易感位点和基因鉴定

全基因组关联研究鉴定了与前列腺癌风险相关的遗传变异位点。然而,这些变异只能解释一部分前列腺癌的风险的遗传组成,并且那些与前列腺癌风险相关的基因还没有完全鉴定。最近,有研究人员为了发现新的前列腺癌遗传位点和之前已经鉴定位点的可能的发病基因,研究人员在具有欧洲血统的79194个案例和61112个对照中进行了全基因组关联分析。研究发现,他们在137个基因中发现的显著的相关性(P<2.61×10-6